Fintel reports that on September 21, 2023, Cantor Fitzgerald reiterated coverage of Humacyte (NASDAQ:HUMA) with a Overweight recommendation.
Analyst Price Forecast Suggests 151.53% Upside
As of August 31, 2023, the average one-year price target for Humacyte is 7.40. The forecasts range from a low of 3.54 to a high of $16.80. The average price target represents an increase of 151.53% from its latest reported closing price of 2.94.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Humacyte is 1MM, an increase of 4,445.16%. The projected annual non-GAAP EPS is -0.99.
What is the Fund Sentiment?
There are 165 funds or institutions reporting positions in Humacyte. This is an increase of 4 owner(s) or 2.48% in the last quarter. Average portfolio weight of all funds dedicated to HUMA is 0.05%, an increase of 29.76%. Total shares owned by institutions increased in the last three months by 18.60% to 15,225K shares. 
The put/call ratio of HUMA is 0.22, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,621K shares representing 1.57% ownership of the company. No change in the last quarter.
IWM - iShares Russell 2000 ETF holds 1,426K shares representing 1.38% ownership of the company. In it's prior filing, the firm reported owning 1,189K shares, representing an increase of 16.59%. The firm increased its portfolio allocation in HUMA by 2.29% over the last quarter.
Geode Capital Management holds 1,102K shares representing 1.07% ownership of the company. In it's prior filing, the firm reported owning 1,054K shares, representing an increase of 4.36%. The firm decreased its portfolio allocation in HUMA by 12.43% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 758K shares representing 0.73% ownership of the company. In it's prior filing, the firm reported owning 770K shares, representing a decrease of 1.63%. The firm decreased its portfolio allocation in HUMA by 13.12% over the last quarter.
Prescott General Partners holds 568K shares representing 0.55% ownership of the company. No change in the last quarter.
Humacyte Background Information
(This description is provided by the company.)
Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
